Evidence map›Paper›PMID 32944516›Full record

ArticleTranslational andrology and urology2020

How to deal with steroids use in the management of metastatic prostate cancer during pandemic.

Michael Baboudjian, Guillaume Ploussard, Shahrokh F Shariat, Piet Ost, Alberto Briganti, Morgan Roupret, Benjamin Pradere

Open access · diamondAbstract readEditorial
In one paragraph

Article in Translational andrology and urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 5 countries.

Michael BaboudjianDepartment of Urology and Kidney Transplantation, Conception Academic Hospital, APHM, Aix-Marseille University, Marseille, France.
Guillaume PloussardDepartment of Urology, Clinique La Croix du Sud, Quint-Fonsegrives, France.
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
Piet OstDepartment of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium.
Alberto BrigantiDepartment of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Morgan RoupretDepartment of Urology, Pitié-Salpêtrière Hospital, AP-HP, Predictive Onco-urology, GRC n°5, Sorbonne University, Paris, France.
Benjamin PradereDepartment of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
Ghent University Hospital · BEHôpital de la Conception · FRIRCCS Ospedale San Raffaele · ITMedical University of Vienna · ATSechenov University · RUSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32944516
PMCPMC7475678
OpenAlexW3042512779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.